Volastra Therapeutics
Clinical stage biotech developing a powerful new class of cancer therapies exploiting chromosomal instability.
New York, United States
41 employees
Series Unknown
Total: $119.00M
Biotechnology, Life Sciences
General Information
Get notified when Volastra Therapeutics moves
Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.
Track Volastra Therapeutics
Get real-time alerts for funding, hiring, news, and 40+ signal types.
See how it worksDiscover More
United States Market
Biotechnology
About Volastra Therapeutics
Taxonomy: Biotech, Cancer Therapies, Chromosomal Instability, Drug Discovery, Therapeutics, Synthetic Lethal Pipeline, Immune Activation, KIF18A Inhibitors, Metastatic Cancers, Clinical Trials, New York-based, Cancer Treatment, Research and Development, Innovative Therapies
Funding Rounds & Investors (4)
View All| Funding Stage | Amount | Investors | Lead Investors | Date |
|---|---|---|---|---|
| Venture Round | •••••• | - | 30 May 2024 | |
| Series A | •••••• | 8 |
|
07 Mar 2023 |
| Seed Round | •••••• | 2 |
|
06 Apr 2021 |
| Seed Round | •••••• | - | 11 Feb 2020 |
Volastra Therapeutics Alternatives & Competitors
Pioneering the future of cancer treatment with breakthrough targeted therapies and innovative diseas...
A leading precision oncology company focused on synthetic lethality
Dedicated to the discovery, development, and commercialization of novel targeted therapies to treat...
FAQ About Volastra Therapeutics
Don't just browse. Track.
Signal Tracker monitors Volastra Therapeutics and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.
